Management of Suspected Heparin-Induced Thrombocytopenia (HIT)

Initial Assessment and Management

When HIT is suspected, immediately discontinue all forms of heparin and initiate therapeutic-dose non-heparin anticoagulation, even before laboratory confirmation, as recommended by the American Society of Hematology 1, 2, 3
Calculate the 4T score to determine pre-test probability of HIT, with a low probability (≤3 points) allowing HIT to be excluded, an intermediate probability (4-5 points) requiring heparin stoppage and alternative anticoagulation, and a high probability (≥6 points) necessitating immediate heparin stoppage and therapeutic-dose alternative anticoagulation, according to the American College of Chest Physicians 2, 3, 4
Stop all forms of heparin, including heparin flushes and heparin-coated catheters, and remove all potential sources of heparin exposure, as advised by the American Heart Association 1, 3
Start therapeutic-dose non-heparin anticoagulant immediately due to high thrombotic risk in HIT, without waiting for laboratory confirmation if clinical suspicion is intermediate or high, as recommended by the American College of Cardiology 1, 2, 3

Argatroban, a direct thrombin inhibitor, is preferred in renal impairment (creatinine clearance <30 mL/min) and should be initiated at a dose of 2 mcg/kg/min as continuous IV infusion, with monitoring of aPTT to maintain 1.5-3 times baseline value, according to the European Society of Cardiology 1, 3
Bivalirudin, a direct thrombin inhibitor with a shorter half-life, is useful for procedures requiring short-acting anticoagulation but is not recommended in severe renal impairment, as stated by the American Society of Hematology 1, 3
Danaparoid, a heparinoid with mainly anti-Xa activity, requires monitoring of anti-Xa activity and is not recommended in severe renal failure, according to the American College of Chest Physicians 1, 3
Fondaparinux, a factor Xa inhibitor, is an option for stable patients without severe renal or hepatic impairment and does not require specific monitoring, as recommended by the European Society of Cardiology 1, 3

In severe HIT, argatroban or bivalirudin with strict biological monitoring is preferred, as advised by the American Heart Association 1, 3
In severe renal impairment, argatroban is the preferred agent, according to the American Society of Nephrology 1, 3
In severe hepatic impairment, bivalirudin, danaparoid, or fondaparinux may be used, as stated by the American Association for the Study of Liver Diseases 1, 3

Wait for platelet count recovery (>150,000/μL or return to baseline) before transitioning to vitamin K antagonists (VKAs), as recommended by the American College of Cardiology 1, 3
Avoid VKAs in the acute phase of HIT, as they can potentially cause venous limb gangrene, according to the American Society of Hematology 3
Overlap parenteral anticoagulant with oral agent for at least 5 days, as advised by the American College of Chest Physicians 3

Do not give platelet transfusions, as they may worsen thrombosis in HIT patients, according to the American Society of Hematology 3
Do not wait for laboratory confirmation before stopping heparin if clinical suspicion is high, as recommended by the American Heart Association 1, 2
Do not use prophylactic doses of alternative anticoagulants - therapeutic doses are required, according to the American College of Cardiology 1, 3
Avoid re-exposure to heparin, especially within 3 months of HIT diagnosis, as stated by the American Society of Hematology 3

Document HIT diagnosis in medical records, as recommended by the American Medical Association 3
Consider extended anticoagulation (3-6 months) depending on the clinical situation, according to the American College of Chest Physicians 3
For future anticoagulation needs, use oral anticoagulants (VKA or DOAC) or fondaparinux, as advised by the American Heart Association 3

The American Society of Anesthesiologists recommends that for patients with acute HIT, surgery should be postponed beyond the first month if possible, to minimize the risk of thrombotic complications 5, 6
In cases where surgery cannot be delayed, the use of short-acting anticoagulants like argatroban or bivalirudin is recommended, with argatroban stopped 4 hours before the procedure and bivalirudin stopped 2 hours before the procedure 5, 6
The Anaesthesia society suggests that in postoperative care, if prolonged anticoagulation is needed and bleeding risk is controlled, treatment with fondaparinux or an oral anticoagulant (VKA or DOAC) is preferred 5

The Anaesthesia society recommends against prescribing an oral antiplatelet agent to treat acute HIT, as it may not effectively prevent thrombosis 5
The Anaesthesia society also advises against the insertion of an inferior vena cava filter in the acute phase of HIT, due to the potential for increased thrombotic risk 5
The use of IV immunoglobulins as first-line treatment for acute HIT is not recommended by the Anaesthesia society 5

The American College of Chest Physicians recommends obtaining a baseline platelet count before starting heparin and repeating it 24 hours later if feasible, as rapid-onset HIT can occur within 24 hours in patients with circulating HIT antibodies 7
In patients with recent heparin exposure (within 100 days), it is essential to monitor platelet counts closely, as the risk of HIT is higher 7
If a patient develops fever, chills, hypertension, tachycardia, dyspnea, chest pain, or cardiopulmonary symptoms within 30 minutes of an IV heparin bolus, immediately check platelet count, as this presentation is strongly suggestive of acute HIT 7

The 4T score is less reliable in post-cardiac surgery patients, and a "biphasic" platelet count pattern - initial postoperative drop followed by recovery, then a second drop - strongly suggests HIT 7